Plasmacytoid dendritic cell-based cancer vaccines

Eric Halioua, PDC*line Pharma, Liege, Belgium, provides an overview of PDC*line, a novel cell line derived from plasmacytoid dendritic cells (PDCs) in the bones of patients with leukemia. The cell line is more potent than allogeneic or autologous myeloid cells and are not rejected in humans. He additionally highlights the ease of manufacturing cancer vaccines from PDC*line due to the consistency of the cell line. This interview was conducted during Meeting on the Mediterranean 2022.